Independent Consultant, formerly Director Corporate Development, GSK
James has recently completed the divestment of the meningococcal vaccines business to Pfizer in a €150m transaction. As the head of the transaction team he led the auction process and deal discussions with the potential acquiring companies, the business carve-out from the GSK infrastructure, and the contract negotiations and approvals with the EC regulator.
James has led a number of significant transactions at GSK, including the strategic collaboration and equity investment with GlycoVaxyn Zurich leading to the $190m acquisition of the company. He also negotiated the in-licensing of the recombinant polio vaccine as part of the joint venture with India’s Biological E. James has been a key member of the Business Team for the DTP Neisseria products, developing the strategy and negotiations with Novartis, which has been a key part of the $6 billion
acquisition completed this year.
Prior to joining GSK, he has held Board level commercial roles in UK BioPharma following an international career with AstraZeneca in Europe, China and USA. At Summit Plc, the publicly listed rare genetic diseases company, James was Chief Business Officer leading deals worth over $150m with Biomarin and the acquisition of Daniolabs. At Cellzome Inc, a proteomics platform company based in Cambridge UK he led partnership deals worth over $145m with Novartis, Johnson & Johnson and Bayer Healthcare. As CEO of Oxford Epigenetics the oncology company, James developed the business plan for the university spin-out and led the seed financing with Sofinnova. James has worked as a non-executive director with Karus Therapeutics, the IP Group (London) and ISIS Innovation (Oxford).
At AstraZeneca, James led the transaction team based in Hong Kong and China for a major joint venture investment near Shanghai and the corporate holding company and partnership with Sinopharm in Beijing. As part of this ransaction he worked at senior levels with the Chinese regulator and also raised financing with Bank of China. As Head of Biotechnology BD at AstraZeneca’s plant genetics business he led the R&D commercialisation strategy and managed the BD team concluding partnership deals worth over $200m in the US, Europe and Japan with Incyte, Maxygen, JT Biosciences. He also held commercial roles during his early career in the USA and UK. James brings extensive business strategy experience and a track record of deal-making, broad international experience and leadership of business development teams.